Logo image of CLNN

CLENE INC (CLNN) Stock Fundamental Analysis

NASDAQ:CLNN - Nasdaq - US1856342019 - Common Stock - Currency: USD

4.43  -0.08 (-1.77%)

After market: 4.41 -0.02 (-0.45%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CLNN. CLNN was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of CLNN have multiple concerns. CLNN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLNN has reported negative net income.
CLNN had a negative operating cash flow in the past year.
CLNN had negative earnings in each of the past 5 years.
In the past 5 years CLNN always reported negative operating cash flow.
CLNN Yearly Net Income VS EBIT VS OCF VS FCFCLNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

CLNN has a Return On Assets of -114.11%. This is in the lower half of the industry: CLNN underperforms 79.04% of its industry peers.
Industry RankSector Rank
ROA -114.11%
ROE N/A
ROIC N/A
ROA(3y)-59.09%
ROA(5y)-41.29%
ROE(3y)-456.82%
ROE(5y)-1408.41%
ROIC(3y)N/A
ROIC(5y)N/A
CLNN Yearly ROA, ROE, ROICCLNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

1.3 Margins

CLNN's Gross Margin of 78.62% is amongst the best of the industry. CLNN outperforms 86.50% of its industry peers.
In the last couple of years the Gross Margin of CLNN has grown nicely.
CLNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.93%
GM growth 5YN/A
CLNN Yearly Profit, Operating, Gross MarginsCLNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

CLNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLNN has been reduced compared to 1 year ago.
CLNN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CLNN has an improved debt to assets ratio.
CLNN Yearly Shares OutstandingCLNN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
CLNN Yearly Total Debt VS Total AssetsCLNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -15.03, we must say that CLNN is in the distress zone and has some risk of bankruptcy.
CLNN has a Altman-Z score of -15.03. This is amonst the worse of the industry: CLNN underperforms 82.06% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.03
ROIC/WACCN/A
WACC10.99%
CLNN Yearly LT Debt VS Equity VS FCFCLNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

CLNN has a Current Ratio of 0.83. This is a bad value and indicates that CLNN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.83, CLNN is not doing good in the industry: 90.94% of the companies in the same industry are doing better.
A Quick Ratio of 0.82 indicates that CLNN may have some problems paying its short term obligations.
CLNN has a Quick ratio of 0.82. This is amonst the worse of the industry: CLNN underperforms 90.59% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.82
CLNN Yearly Current Assets VS Current LiabilitesCLNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

CLNN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.83%, which is quite impressive.
The Revenue for CLNN has decreased by -41.53% in the past year. This is quite bad
Measured over the past years, CLNN shows a very strong growth in Revenue. The Revenue has been growing by 46.03% on average per year.
EPS 1Y (TTM)43.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205%
Revenue 1Y (TTM)-41.53%
Revenue growth 3Y46.03%
Revenue growth 5YN/A
Sales Q2Q%-19.44%

3.2 Future

Based on estimates for the next years, CLNN will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.31% on average per year.
Based on estimates for the next years, CLNN will show a very strong growth in Revenue. The Revenue will grow by 230.09% on average per year.
EPS Next Y55.04%
EPS Next 2Y29.02%
EPS Next 3Y21.51%
EPS Next 5Y19.31%
Revenue Next Year-34.68%
Revenue Next 2Y-28.68%
Revenue Next 3Y337.57%
Revenue Next 5Y230.09%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLNN Yearly Revenue VS EstimatesCLNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CLNN Yearly EPS VS EstimatesCLNN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20 30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLNN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLNN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLNN Price Earnings VS Forward Price EarningsCLNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLNN Per share dataCLNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as CLNN's earnings are expected to grow with 21.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.02%
EPS Next 3Y21.51%

More info and screens

0

5. Dividend

5.1 Amount

CLNN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLENE INC

NASDAQ:CLNN (2/21/2025, 8:10:00 PM)

After market: 4.41 -0.02 (-0.45%)

4.43

-0.08 (-1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-11 2025-03-11/amc
Inst Owners13.69%
Inst Owner Change-94.4%
Ins Owners25.17%
Ins Owner Change0.55%
Market Cap36.90M
Analysts81.67
Price Target51.2 (1055.76%)
Short Float %2.14%
Short Ratio1.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.96%
Min EPS beat(2)9.66%
Max EPS beat(2)30.25%
EPS beat(4)3
Avg EPS beat(4)12.12%
Min EPS beat(4)-10.29%
Max EPS beat(4)30.25%
EPS beat(8)5
Avg EPS beat(8)10.75%
EPS beat(12)8
Avg EPS beat(12)25.79%
EPS beat(16)10
Avg EPS beat(16)8.37%
Revenue beat(2)0
Avg Revenue beat(2)-8.01%
Min Revenue beat(2)-10.78%
Max Revenue beat(2)-5.23%
Revenue beat(4)1
Avg Revenue beat(4)-10.72%
Min Revenue beat(4)-41.81%
Max Revenue beat(4)14.94%
Revenue beat(8)3
Avg Revenue beat(8)17.19%
Revenue beat(12)5
Avg Revenue beat(12)21.56%
Revenue beat(16)8
Avg Revenue beat(16)37.09%
PT rev (1m)11.14%
PT rev (3m)7.57%
EPS NQ rev (1m)-0.71%
EPS NQ rev (3m)-1210.34%
EPS NY rev (1m)0%
EPS NY rev (3m)1.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 87.65
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.28
EYN/A
EPS(NY)-3.49
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.84
OCFYN/A
SpS0.05
BVpS-0.5
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -114.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.62%
FCFM N/A
ROA(3y)-59.09%
ROA(5y)-41.29%
ROE(3y)-456.82%
ROE(5y)-1408.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.93%
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.24%
Cap/Sales 12.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.82
Altman-Z -15.03
F-Score3
WACC10.99%
ROIC/WACCN/A
Cap/Depr(3y)221.91%
Cap/Depr(5y)N/A
Cap/Sales(3y)445.77%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-205%
EPS Next Y55.04%
EPS Next 2Y29.02%
EPS Next 3Y21.51%
EPS Next 5Y19.31%
Revenue 1Y (TTM)-41.53%
Revenue growth 3Y46.03%
Revenue growth 5YN/A
Sales Q2Q%-19.44%
Revenue Next Year-34.68%
Revenue Next 2Y-28.68%
Revenue Next 3Y337.57%
Revenue Next 5Y230.09%
EBIT growth 1Y18.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.47%
EBIT Next 3Y12.42%
EBIT Next 5Y39.19%
FCF growth 1Y47.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.22%
OCF growth 3YN/A
OCF growth 5YN/A